Dr. Abdul-Badi Abou-Samra

Dr. Abdul-Badi Abou-Samra is one of the most distinguished endocrinologists in the Arabian Gulf region, currently serving as a senior consultant at Hamad Medical Corporation in Doha, Qatar. With more than 30 years of clinical and academic experience, he has established himself as a leading authority in diabetes management, thyroid disorders, metabolic syndrome, and pituitary disease. Dr. Abou-Samra has contributed extensively to endocrinology research, with numerous peer-reviewed publications in high-impact international journals. His dual role as clinician and academic has allowed him to translate cutting-edge research directly into improved patient outcomes at one of the region's most advanced tertiary care institutions.

Dr. Abou-Samra earned his MD from a leading medical university, followed by a PhD in endocrine physiology that laid the foundation for his research career. He completed specialty training in endocrinology and metabolism at internationally accredited institutions in Europe and North America. His post-doctoral research focused on insulin signalling pathways and glucose regulation. He has held academic appointments and visiting fellowships at several renowned universities, deepening his expertise in the molecular mechanisms underlying diabetes and thyroid disease. He is a recognised educator who has trained numerous endocrinology fellows throughout his career at Hamad Medical Corporation.

Dr. Abou-Samra's clinical expertise spans the full spectrum of endocrine disorders. He is highly skilled in the management of Type 1 and Type 2 diabetes using advanced technologies including insulin pump therapy (CSII) and continuous glucose monitoring (CGM) systems. He performs ultrasound-guided fine needle aspiration (FNA) of thyroid nodules and provides comprehensive care for thyroid cancer, hyperthyroidism, and hypothyroidism. His pituitary expertise includes evaluation and management of pituitary adenomas, growth hormone disorders, and adrenal insufficiency. He also manages metabolic syndrome, polycystic ovary syndrome, and osteoporosis within an integrated endocrine framework.

Hamad Medical Corporation is Qatar's primary academic health system and one of the most advanced healthcare networks in the Middle East, attracting international patients from across the Gulf Cooperation Council and beyond. Dr. Abou-Samra's trilingual fluency in Arabic, English, and French makes him accessible to a wide international patient base. The hospital offers dedicated international patient services including visa assistance, accommodation referrals, teleconsultation options, and a structured care coordination pathway. Qatar's modern infrastructure and world-class hospitals make it an increasingly attractive medical destination for patients from the Arab world, South Asia, and Europe.

Dr. Abou-Samra has received multiple accolades for his contributions to endocrinology and diabetes research across the Arab world. He has been recognised by the Endocrine Society (USA), the European Association for the Study of Diabetes (EASD), and the Qatar Diabetes Association for outstanding scientific contributions. He is frequently invited as a keynote speaker at regional and international endocrinology conferences and has served on editorial boards of peer-reviewed journals.